Parkinson's disease
Conditions
Interventions
High-dose ganglioside infusion group:intravenous infusion, 400mg on the first day, reduced to 200mg daily thereafte
Low-dose ganglioside infusion group:intravenous infusion, 40mg daily
Normal group:intravenous infusion, equal volume of saline
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? The patient was diagnosed with Parkinson's disease or movement disorders by at least 2 neurology specialists; ? Patients with good compliance, can actively cooperate with the relevant treatment and no allergic reaction to the treatment drugs; ? Patients and their families gave informed consent and signed informed consent
Exclusion criteria
Exclusion criteria: ? Pregnant or lactating women; ? Patients with end-stage disease; ? Patients who are participating in or have participated in other clinical trials within 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Parkinson's Disease Rating Scale; | — |
Countries
China
Contacts
Public ContactWang Xuejing
Outcome results
None listed